Immunosignaturing can detect products from molecular markers in brain cancer

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Hughes, Alexa K ^a   Cichacz, Zbigniew ^a   Scheck, Adrienne ^b   Coons, Stephen W ^b   Johnston, Stephen Albert ^a   Stafford, Phillip ^a  

^a ARIZONA STATE UNIVERSITY   (United States)

^b BARROW NEUROLOGICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE;

ADULT; ARTICLE; ASTROCYTOMA; BLOOD SAMPLING; BRAIN CANCER; BRAIN TUMOR; CANCER CLASSIFICATION; CANCER GRADING; CANCER SURVIVAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DRUG EFFICACY; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOLOGICAL PROCEDURES; IMMUNOSIGNATURING; MAJOR CLINICAL STUDY; MALE; OLIGODENDROGLIOMA; REPRODUCIBILITY; VALIDITY;

ADULT; ANTIBODIES, NEOPLASM; BRAIN NEOPLASMS; CASE-CONTROL STUDIES; COMPUTATIONAL BIOLOGY; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PROTEIN ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84862901532     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040201     Document Type: Article

References (43)

1. Nolen B, Langmead C, Choi S, Lomakin A, Marrangoni A, et al. (2011) Serum biomarker profiles as diagnostic tools in lung cancer. Cancer Biomarkers 10(1): 3-13.
2. Brand R, Nolen B, Zeh H, Allen P, Eloudeidi M, et al. (2011) Serum biomarker panels for the detection of pancreatic cancer. Clin. Cancer Res. 17(4): 805-816.
3. Gnjatic S, Ritter E, Bachler MW, Giese NA, Brors B, et al. (2010) Seromic profiling of ovarian and pancreatic cancer. P Natl Acad Sci USA 107(11): 5088-5093.
4. Dunn GP, Old LJ, Schreiber RD, (2004) The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21(2): 137-148.
5. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD, (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3(11): 991-998.
6. Sreekumar A, Laxman B, Rhodes DR, Bhagavathula S, Harwood J, et al. (2004) Humoral immune response to methylacyl-CoA racemase and prostate cancer. Journal of the National Cancer Institute 96(11): 834-843.
7. Ho M, Hassan R, Zhang J, Wang Q-c, Onda M, et al. (2005) Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients. Clinical Cancer Research 11(10): 3814-3820.
8. Cenci S, Sitia R, (2007) Managing and exploiting stress in the antibody factory. FEBS Letters 581(19): 2652-3657.
9. Sulzer B, van Hemmen JL, Neumann AU, Behn U, (1993) Memory in idiotypic networks due to competition between proliferation and differentiation. Bulletin of Mathematical Biology 55(6): 1133-1182.
10. Cooperman J, Neely R, Teachey DT, Grupp S, Choi JK, (2004) Cell division rates of primary human precursor B cells in culture reflect in vivo rates. Stem Cells 22: 1111-1120.
11. Forster I, Rajewsky K, (1990) The bulk of the peripheral B-cell pool in mice is stable and not rapidly renewed from the bone marrow. P Natl Acad Sci USA 87: 4781-4784.
12. Hao Z, Rajewsky K, (2001) Homeostasis of peripheral B cells in the absence of B cell Influx from the bone marrow. The Journal of Experimental Medicine 194(8): 1151-1164.
13. Anderson NL, Anderson NG, (2002) The human plasma proteome. Molecular & Cellular Proteomics 1(11): 845-867.
14. Lutz AM, Willmann JK, Drescher CW, Ray P, Cochran FV, et al. (2011) Early diagnosis of ovarian carcinoma: Is a solution in sight? Radiology 259: 329-345.
15. Geijersstam V, Kibur M, Wang Z, Koskela P, Pukkala E, et al. (1998) Stability over time of serum antibody levels to human papillomavirus type 16. The Journal of Infectious Diseases 177(6): 1710-1714.
16. Merbl Y, Itzchak R, Vider-Shalit T, Louzoun Y, Quintana FJ, et al. (2009) A systems immunology approach to the host-tumor interaction: large-scale patterns of natural autoantibodies distinguish healthy and tumor-bearing mice. Plos One 4(6): e6053.
17. Mintz PJ, Kim J, Do K-A, Wang X, Zinner RG, et al. (2003) Fingerprinting the circulating repertoire of antibodies from cancer patients. Nat Biotech 21(1): 57-63.
18. Desmetz C, Maudelonde T, Mange A, Solassol J, (2009) Identifying autoantibody signatures in cancer: a promising challenge. Expert Reviews in Proteomics 6(4): 377-386.
19. Fischer E, Kobold S, Kleber S, Kubuschok B, Braziulis E, et al. (2010) Cryptic epitopes induce high-titer humoral immune response in patients with cancer. J. Immunol. 185(5): 3095-3102.
20. Mou Z, He Y, Wu Y, (2009) Immunoproteomics to identify tumor-associated antigens eliciting humoral response. Cancer Letters 278(2): 123-129.
21. Kijanka G, Murphy D, (2009) Protein arrays as tools for serum autoantibody marker discovery in cancer. Journal of Proteomics 72: 936-944.
22. Wheeler CJ, Black KL, Liu G, Mazer M, Zhang X-x, et al. (2008) Vaccination elicits correlated immune and clinical responses in Glioblastoma multiforme patients. Cancer Research 68(14): 5955-5964.
23. Balagurunathan Y, Morse DL, Hostetter G, Shanmugam V, Stafford P, et al. (2008) Gene expression profiling-based identification of cell-surface targets for developing multimeric ligands in pancreatic cancer. Molecular Cancer Therapeutics 7(9): 3071-3080.
24. Hudson ME, Pozdnyakova I, Haines K, Mor G, Snyder M, (2007) Identification of differentially expressed proteins in ovarian cancer using high-density protein microarrays. P Natl Acad Sci USA 104(44): 17494-17499.
25. Oyama T, Sykes KF, Samli KN, Minna JD, Johnston SA, et al. (2003) Isolation of lung tumor specific peptides from a random peptide library: generation of diagnostic and cell-targeting reagents. Cancer Letters 202(2): 219-230.
26. Stafford P, Halperin RF, Legutki JB, Magee DM, Galgiani J, et al. (2012) Physical characterization of the 'Immunosignaturing Effect'. Molecular & Cellular Proteomics doi:10.1074/mcp.M111.011593.
27. Stafford P, Johnston S, (2011) Microarray technology displays the complexities of the humoral immune response. Expert Review of Molecular Diagnostics 11(1): 5-8.
28. Restrepo L, Stafford P, Magee DM, Johnston SA, (2011) Application of immunosignatures to the assessment of Alzheimer's disease. Ann. Neurol 70(2): 286-295.
29. Brown J, Stafford P, Johnston S, Dinu V, (2011) Statistical methods for analyzing immunosignatures. BMC Bioinformatics 12(1): 349.
30. Chase BA, Johnston SA, Legutki JB, (2012) Evaluation of biological sample preparation for immunosignature based diagnostics. Clinical and Vaccine Immunology doi:10.1128/CVI.05667-11.
31. Jemal A, Siegel R, Xu J, Ward E, (2010) Cancer statistics, 2010. CA: A Cancer Journal for Clinicians.
32. Ostrom Q, Barnholtz-Sloan J, (2011) Current state of our knowledge on brain tumor epidemiology. Current Neurology and Neuroscience Reports 11(3): 329-335.
33. Holland EC, (2000) Glioblastoma multiforme: The terminator. P Natl Acad Sci USA 97(12): 6242-6244.
34. Coons SW, Johnson PC, Scheithauer BW, Yates AJ, Pearl DK, (1997) Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 79(7): 1381-1393.
35. Restrepo L, Stafford P, Magee DM, Johnston SA, (2011) Application of immunosignatures to the assessment of Alzheimer's disease. Annals of Neurology 70(2): 286-295.
36. Legutki JB, Magee DM, Stafford P, Johnston SA, (2010) A general method for characterization of humoral immunity induced by a vaccine or infection. Vaccine 28(28): 4529-4537.
37. Halperin R, Stafford P, Legutki JB, Johnston SA, (2010) Exploring antibody recognition of sequence space through random-sequence peptide microarrays. Molecular and Cellular Proteomics 28(1): e101230.101236.
38. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New England Journal of Medicine 352(10): 987-996.
39. Hegi ME, Diserens A-C, Godard S, Dietrich P-Y, Regli L, et al. (2004) Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in Glioblastoma patients treated with temozolomide. Clinical Cancer Research 10(6): 1871-1874.
40. Ishii D, Natsume A, Wakabayashi T, Hatano H, Asano Y, et al. (2007) Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas. Neurol Med Chir (Tokyo) 47(8): 341-349.
41. Team RDC (2005) R: A Language and Environment for Statistical Computing. CRAN (Comprehensive R Archive Network), Vienna, Austria.
42. Smith KA, Ashby LS, Gonzalez LF, Brachman DG, Thomas T, et al. (2008) Prospective trial of gross-total resection with gliadel wafers followed by early postoperative gamma knife radiosurgery and conformal fractionated radiotherapy as the initial treatment for patients with radiographically suspected, newly diagnosed Glioblastoma multiforme. Special Supplements 109(6): 106-117.
43. Boltz K, Gonzalez M, Stafford P, Johnston SA, Svarovsky S, (2009) Peptide microarrays for carbohydrate recognition. Analyst 134: 650-652.